179 related articles for article (PubMed ID: 33147674)
1. Severe erosive gingivostomatitis in a patient treated by vedolizumab.
Semeria L; Dadban A; Brazier F; Fumery M; Ikoli JF; Arnault JP; Adas A; Dairi M; Lok C; Chaby G
Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147674
[TBL] [Abstract][Full Text] [Related]
2. Vedolizumab-induced acute pancreatitis: the first reported clinical case.
Picardo S; So K; Venugopal K; Chin M
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29305366
[TBL] [Abstract][Full Text] [Related]
3. Acneiform eruption induced by vedolizumab.
Magdaleno-Tapial J; Ferrer-Guillén B; Valenzuela-Oñate C; Esteve-Martínez A
Dermatol Online J; 2018 Oct; 24(10):. PubMed ID: 30677821
[TBL] [Abstract][Full Text] [Related]
4. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
6. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
7. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
8. Acute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab.
Lin E; Katz S
Inflamm Bowel Dis; 2020 Apr; 26(5):e44. PubMed ID: 32100867
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
[TBL] [Abstract][Full Text] [Related]
10. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab-induced acne in inflammatory bowel disease.
Gilhooley E; Doherty G; Lally A
Int J Dermatol; 2018 Jun; 57(6):752-753. PubMed ID: 29654701
[No Abstract] [Full Text] [Related]
12. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series.
Varkas G; Thevissen K; De Brabanter G; Van Praet L; Czul-Gurdian F; Cypers H; De Kock J; Carron P; De Vos M; Hindryckx P; Arts J; Vanneuville I; Schoenaers P; Claerhout B; Abreu M; Van den Bosch F; Elewaut D
Ann Rheum Dis; 2017 May; 76(5):878-881. PubMed ID: 27899374
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab-associated pulmonary manifestations in children with ulcerative colitis.
Cucinotta U; Dipasquale V; Costa S; Pellegrino S; Ramistella V; Romano C
J Clin Pharm Ther; 2022 Feb; 47(2):254-256. PubMed ID: 34278581
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D;
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.
Van den Berghe N; Verstockt B; Tops S; Ferrante M; Vermeire S; Gils A
J Gastroenterol Hepatol; 2019 Jul; 34(7):1175-1181. PubMed ID: 30589948
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of vedolizumab for inflammatory bowel disease.
Loftus EV; Feagan BG; Panaccione R; Colombel JF; Sandborn WJ; Sands BE; Danese S; D'Haens G; Rubin DT; Shafran I; Parfionovas A; Rogers R; Lirio RA; Vermeire S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1353-1365. PubMed ID: 32876349
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
19. Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis.
Rizos ED; Antonogiannaki EM; Chatzidakis A; Kallieri M; Tsilogianni Z; Manali ED; Economopoulos N; Triantafyllou K; Papiris SA; Polymeros D
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1057-e1059. PubMed ID: 34074983
[TBL] [Abstract][Full Text] [Related]
20. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]